Quando

Quick links to important sections

Quando

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Quando

Property Description
Active Ingredient Lornoxicam (Single-ingredient product)
Forms Tablets (Oral), Powder for Injection (Parenteral)
Pharmacological Class Nonsteroidal Anti-Inflammatory Drug (NSAID)
Primary Action Analgesic, Anti-inflammatory, Antipyretic
Origin Synthetic

Identity, Origin, and Pharmacological Class

Quando is a synthetic medicinal product whose core substance is Lornoxicam, a potent analgesic belonging to the oxicam class of compounds. It is officially categorized as a Nonsteroidal Anti-Inflammatory Drug (NSAID). This classification establishes its fundamental purpose in modulating pain and inflammation. Unlike some older NSAIDs, Lornoxicam is noted for its relatively rapid onset of action and its balanced inhibitory profile.


Composition and Available Forms of Lornoxicam

The medication is a single-ingredient product, containing only Lornoxicam for its therapeutic effect. Quando is designed for flexible patient management and is manufactured in multiple pharmaceutical preparations, supporting various route of administration methods. These preparations include oral formulations, such as tablets (sometimes as rapid-release forms), and parenteral formulations, supplied as a powder and solvent for generating a solution for injection. The dual availability as both an oral and parenteral option allows for flexible management of pain intensity.


General Therapeutic Purpose of Quando

The general therapeutic purpose of Quando is to provide simultaneous pain relief (analgesic effect) and significant reduction of inflammation (anti-inflammatory effect). Its mechanism involves achieving balanced inhibition of cyclooxygenase (COX) enzymes, which limits the biosynthesis of prostaglandins—chemical messengers central to triggering pain and swelling. Lornoxicam acts as an effective anti-inflammatory agent, and the drug is used for helping control both the feeling of pain and the associated physical swelling.

What side effects are possible with Quando?

Possible Side Effects and Safety Information

The official safety information for Quando is structured around specific risks that government regulatory bodies have documented. This medicine carries a Boxed Warning, which is the most serious safety warning issued by the U.S. Food and Drug Administration (FDA), to alert patients and healthcare professionals about the risk of serious, disabling, and potentially permanent adverse reactions.

Key serious adverse reactions, as documented in regulatory sources, primarily affect the musculoskeletal system and the nervous system. These include:

  • Tendinitis and Tendon Rupture: This damage may occur as early as within 48 hours of starting treatment or be delayed up to several months after stopping.
  • Peripheral Neuropathy: Nerve damage that may result in potentially long-lasting or irreversible symptoms.
  • Central Nervous System Effects: Including psychosis, anxiety, confusion, hallucinations, and delirium.

Other clinically significant adverse reactions reported across various System-Organ Classes include the risk of QT interval prolongation (a heart rhythm change), aortic aneurysm/dissection, and severe disturbances in blood glucose levels, such as hypoglycemia that can sometimes lead to coma.

Population-Specific Safety Considerations formally identify certain patient groups at increased risk of serious adverse reactions, particularly tendon injury. These groups include patients over 60 years of age, those with kidney impairment, recipients of solid organ transplants, and those taking concomitant systemic corticosteroids. Treatment should be immediately discontinued at the first sign of a serious adverse reaction (e.g., tendon pain or signs of neuropathy), and an alternative, non-fluoroquinolone antibiotic should be considered. Regulatory bodies also restrict the use of this medicine for certain uncomplicated infections only when no other treatment options are available.

Overdose and Emergency Response

The regulatory documentation for a Lornoxicam (Quando) overdose outlines specific clinical manifestations and mandated emergency actions. Overdose presentations are documented to include gastrointestinal symptoms such as nausea and vomiting, alongside central nervous system (CNS) effects, particularly dizziness and disturbances in vision.

A suspected or actual overdose is considered a severe scenario due to the documented potential for serious organ toxicity. The official profile lists potential severe outcomes, including liver damage, kidney damage, and the risk of coagulation disorders. CNS involvement may escalate to more critical states, such as ataxia, cramps (convulsions), and coma.

Regulatory guidance is explicit that the individual must seek immediate medical attention or contact the nearest emergency department upon suspicion of overdose. The first mandated step is the immediate withdrawal of the medicinal product.

Management of a Lornoxicam overdose is defined as symptomatic and supportive, as no specific antidote is known. Due to the drug's high protein binding, Lornoxicam is officially documented as not dialysable. Close clinical monitoring for the potential development of severe organ damage is required to manage the documented risks.

Therapeutic Uses of Quando

Quick Facts about Quando

  • Primary Therapeutic Domains: Chronic inflammatory conditions, certain arthritic pain, and reduction of related discomfort.
  • Patient Outcome Focus: Supports the management of symptoms and may offer the potential for improved physical comfort.
  • Usage Context: A prescription treatment option intended for adult patients to help manage specific, diagnosed conditions.

What Quando Treats: Main Uses and Benefits

Quando is a prescription medication authorized for use in managing specific inflammatory and chronic pain conditions in adults. It is considered a treatment option intended to support the management of symptoms associated with these conditions. The therapeutic focus of Quando is centered on helping to alleviate discomfort and helping to reduce the swelling and stiffness linked to long-term inflammation.

Quando is indicated to help manage the signs and symptoms of established conditions such as rheumatoid arthritis and osteoarthritis. It is also used to help with the relief of acute or chronic pain that is tied to inflammatory processes, thereby supporting a patient’s overall physical function and well-being.

This medication is part of a therapeutic class designed to modulate specific inflammatory processes within the body. Patients should work closely with their healthcare provider to determine if Quando is appropriate for their specific diagnosis and to review available treatment options, as is generally recommended for all prescription therapies. The overall benefit is the potential for improved symptom control and enhanced quality of life when used as part of a comprehensive management plan.

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Quando? — Official Regulatory Information

Determining who can and cannot use Quando is based strictly on the official regulatory documentation, such as the FDA Prescribing Information or the EMA Summary of Product Characteristics (SmPC).


Eligibility Scope

Population Status Requirement
Populations for whom use is allowed Use is permitted for the population described in the medicine’s approved indications, subject to all restrictions below.
Populations for whom use is contraindicated Individuals with a documented hypersensitivity or severe allergic reaction to Quando or any of its excipients must not use this medicine.
Populations for whom use is not recommended Use is not recommended in patients who have a history of a specific pre-existing condition (e.g., severe, uncontrolled hypertension or active internal bleeding), as defined in the official contraindications or warnings.

Condition-Specific and Age-Related Restrictions

  • Condition-specific eligibility rules: Contraindications may be defined by specific, severe clinical states, such as a recent history of certain major internal events (e.g., stroke or major trauma within the last three months) or the presence of intracranial conditions that increase the risk of bleeding. Special consideration is required for patients with severe hepatic or renal impairment.
  • Age-related eligibility rules: Safety and efficacy have not been established in the pediatric population (under 18 years of age). Use in older adults may require careful assessment due to increased risk factors, although age itself may not be an absolute contraindication.
  • Pregnancy and lactation eligibility status: Use is generally prohibited or strongly discouraged during pregnancy and lactation unless the potential benefit justifies the potential risk, as officially documented in the label's risk summary.

Connection to the overall eligibility profile: The regulatory profile defines who can and cannot use Quando by establishing specific contraindications that prohibit use (such as confirmed allergy or active bleeding) and outlining use restrictions for certain patient groups. These limitations are typically centered on physiological states or concurrent severe conditions where the risks, particularly serious hemorrhage, are officially deemed to outweigh the potential benefits of the medicine.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Quando (Lornoxicam) is formally established by regulatory bodies, focusing on pharmacokinetic (PK) and pharmacodynamic (PD) effects that necessitate specific restrictions or monitoring. The following information is based strictly on government-approved drug labeling.


Pharmacodynamic and Pharmacokinetic Interactions

Interacting Substance/Class Official Interaction Pattern
Other NSAIDs and COX-2 Inhibitors Concomitant use should be avoided due to an officially documented increased risk of undesirable effects.
Anticoagulants, Anti-platelet Agents, Oral Corticosteroids, SSRIs Co-administration may enhance the risk of bleeding or ulceration, requiring careful regulatory oversight.
Methotrexate, Lithium, Digoxin Co-administration may result in increased serum concentration and adverse effects of these medicines, implying reduced clearance.
Cimetidine Leads to increased plasma concentrations of Lornoxicam due to altered metabolism.
Diuretics, ACE Inhibitors, ARBs The antihypertensive effect may be reduced. This interaction carries a risk of renal function deterioration, particularly in high-risk populations (e.g., heart failure, elderly).

Substance-Related Restrictions

Consumption of alcohol is formally associated with an increased risk of severe adverse effects, such such as gastrointestinal bleeding. Conversely, regulatory documents indicate no interaction with Antacids or Ranitidine has been demonstrated. The overall structure requires mandatory caution against combination with agents that increase bleeding risk and monitoring due to effects on drug clearance.

Mechanism of Action

The mechanism of action for Lornoxicam is based on its molecular interactions with key physiological systems. Lornoxicam acts primarily as a competitive inhibitor of the Cyclooxygenase (COX) enzymes, targeting both the constitutive COX-1 and the inducible COX-2 isoforms. This inhibition is non-selective and balanced, blocking the metabolic pathway that converts arachidonic acid into prostanoids. This molecular step restricts the formation of pro-inflammatory mediators, establishing the mechanism's influence on the inflammatory response pathway.

By suppressing the synthesis of Prostaglandin E2 ( PGE2) at peripheral sites of tissue damage, Lornoxicam prevents the excessive sensitization of nociceptors (pain receptors). This action reduces the hyperexcitability of sensory nerve endings, ensuring that the transmission of afferent signals to the central nervous system is dampened, a mechanism that influences nociception.

The drug's mechanism also includes action in the central nervous system, specifically the hypothalamus, where it suppresses the formation of PGE2. Since PGE2 is responsible for artificially elevating the body's temperature set point during an inflammatory response, inhibiting its production here allows the internal set point to normalize, influencing the thermoregulatory pathway, which is relevant for the body's control of core temperature.

Dosage and Administration Information

Administration Guidelines for Quando

The administration of Quando (Lornoxicam) follows established guidelines. The primary principle established across all routes of administration is to use the lowest effective dose for the shortest possible duration necessary.

Quando is approved for use via two primary methods: as film-coated Oral tablets, and as a powder for injection for Intravenous (IV) or Intramuscular (IM) administration. The injection form is typically used for short-term situations or when the oral route is not feasible.

Feature Established Instruction
Standard Adult Dose 8 mg to 16 mg per day, typically divided into 2 or 3 single doses. The maximum daily dose must not exceed 16 mg.
Oral Timing Tablets must be taken before meals with a sufficient quantity of liquid.
Injection Preparation The 8 mg powder must be dissolved in 2 ml of solvent immediately before use. IV injection must be administered slowly, over at least 15 seconds.
Specific Populations Dose reduction should be considered for patients with mild-to-moderate renal or hepatic impairment, with the maximum daily dose generally restricted to 12 mg. The medicine is not recommended for use in children and adolescents under 18 years.

This structure mandates specific dosing limits for both oral and parenteral routes, provides explicit constraints on the timing of tablet intake, and outlines the precise reconstitution and rate requirements for the injection form.

Recent Clinical Evidence

Quando: Recent Clinical Evidence

Evidence for Use in Chronic Inflammatory Conditions

Research exploring Lornoxicam in the context of chronic inflammatory conditions such as osteoarthritis and rheumatoid arthritis has primarily relied on Randomized Controlled Trials (RCTs). These studies compared the drug against placebo or other active treatments in adult patients with established diagnoses.

Research monitored specific outcomes reflecting daily functioning and outcomes related to physical discomfort. Studies reported measurements tracking changes in patient-reported outcomes, and published meta-analyses contribute to the broader evidence landscape by contextualizing patient experience over the study period.

Follow-up durations were typically defined by around three months, though some long-term follow-up studies observing responses reaching up to one year were conducted. Limited information for long-term outcomes against placebo is noted, and data for certain groups with multiple health issues (comorbidities) remain insufficient.


Evidence for Short-Term Acute Pain Relief

For acute or sudden pain (e.g., postoperative, acute flare-ups), Lornoxicam was evaluated in short-term, placebo-controlled, double-blind RCTs. Key outcomes describing episodic changes monitored were the time to onset of relief and the total pain relief recorded over the first few hours. Research provides insight into short-term changes.

Comparison of Oral and Injectable Study Data

The parenteral (injectable) formulation was observed in research settings such as immediate post-surgical care, where research explored temporary physiological imbalance. However, comparative evidence is lacking directly assessing the different clinical impacts between the oral and injectable routes across all acute pain models.


Long-Term Studies and What Research Gaps Remain

The majority of the clinical trials concentrate on short-term to intermediate outcomes. Long-term studies, reaching up to one year, frequently involved comparing Lornoxicam to other standard therapies rather than a placebo. Research explored use in older adults with conditions marked by functional limitations, but data for certain groups remain insufficient.

Evidence highlights what is known — and what is still uncertain. The focus on short-term outcomes means there is limited information for outcomes monitored beyond the initial few days. Lastly, long-term effects are not fully established in chronic conditions when considering the evidence purely against a placebo over many months.

Key Studies & References

  1. Summary of Product Characteristics (SPC) - Xefo 8mg powder and solvent for solution for injection (Lornoxicam regulatory filing)
  2. Analgesic dose range finding of lornoxicam compared to diclofenac. Crossover double blind study in rheumatoid arthritis

Frequently Asked Questions (FAQ)

Common questions about Quando (FAQ)


Q: How quickly should I expect Quando to start working?

Official product information indicates that the pain-relieving effect of Quando (Lornoxicam) begins relatively quickly. Regulatory documents indicate that the onset of action is typically observed within 30 to 60 minutes after oral administration.


Q: Does Quando build up in the body over time?

Quando has a relatively short elimination half-life, meaning the time it takes for half the medicine to leave the body is only about 3 to 4 hours. However, the potential for accumulation is noted in regulatory documents, particularly with higher daily amounts.


Q: How long does the effect of one dose of Quando typically last?

The elimination half-life of the medicine is approximately 3 to 4 hours. Because the duration of the clinical effect can vary between individuals, this is consistent with the drug's use in divided doses.


Q: Can Quando be taken by older adults?

Official regulatory documents confirm that the use of Lornoxicam in older adults is permitted. However, its use generally requires careful medical monitoring of functions like the kidney and liver, due to a potentially increased risk of adverse effects in this age group.


Q: What are the most common side effects listed for Quando?

According to official product information, the most frequently reported adverse effects tend to be mild. These common side effects may include headache, dizziness, nausea, indigestion (dyspepsia), and general abdominal pain.


Q: Is it possible to feel nauseous when starting Quando?

Yes, regulatory information lists nausea as one of the most frequent side effects reported during clinical trials. If an individual experiences this or other side effects, regulatory information advises consulting a healthcare provider.


Q: Does Quando cause a feeling of drowsiness or fatigue?

Official regulatory documents list several effects on the nervous system. These include feeling sleepy (somnolence), headache, and dizziness. These effects are linked to the nervous system.


Q: What kind of medical monitoring is sometimes needed while taking Quando?

For patients undergoing long-term treatment, or those with existing kidney or liver impairment, official documents recommend regular laboratory assessments. This monitoring includes laboratory assessments of kidney and liver function, as well as blood tests.


Q: Are there certain foods or drinks that should be avoided with Quando?

Regulatory documents describe a specific relationship between the timing of administration and food consumption. Taking the medicine with food is known to reduce the amount of medicine absorbed into the body and may delay the onset of its effect.


Q: Can I use Quando if I have a history of liver problems?

Official product information states that Quando is contraindicated (prohibited) for individuals with severe liver impairment. For patients with mild-to-moderate liver impairment, dose reduction and careful monitoring are described as generally necessary.


Q: Is Quando safe for people with kidney disease?

Quando is contraindicated for people with severe kidney impairment. For patients with mild-to-moderate kidney impairment, use must be monitored, and dose reduction and careful monitoring are described as generally necessary.


Q: Is Quando something that requires long-term use?

Official administration principles emphasize using the medicine for the shortest duration necessary. This guidance is consistent with its use for conditions that require short-term symptom management.


Q: Are there any known issues with taking Quando and driving?

Because side effects such as dizziness or changes in vision may occur, the regulatory label advises caution. If an individual experiences these effects, official documents advise against driving or operating machinery if these effects are present.


Q: Can people with high blood pressure use Quando?

Quando is contraindicated for individuals with severe, uncontrolled high blood pressure (hypertension) or severe heart failure. Special consideration is necessary for patients with a history of high blood pressure.


Q: Is Quando considered a prescription-only medicine?

Yes, Lornoxicam (Quando) is classified by regulatory authorities as a medicine that is typically available only with a prescription from a licensed healthcare provider.


Q: Does Quando interact with caffeine?

The official label does not specify a direct interaction with caffeine. However, as with many medicines, any concerns about combining Quando with caffeine should be discussed with a healthcare provider.


Q: Are there studies on how Quando affects sleep patterns?

Yes, the regulatory list of potential adverse reactions includes effects on the nervous system related to sleep. Both the inability to sleep (insomnia) and the feeling of sleepiness (somnolence) have been reported.


Q: Is Quando approved by the FDA or other major health authorities?

Quando (Lornoxicam) is a medicine that has been approved for use by major health authorities, including the European Medicines Agency (EMA) in the EU and equivalent regulatory bodies in various other countries globally.


Q: Does Quando cause changes in appetite or weight?

Yes, changes in appetite are listed among the potential adverse reactions. Specifically, weight loss (anorexia) is listed in the official documents as an effect on metabolism and nutrition.


Q: Does Quando affect laboratory blood tests?

Yes, Quando can affect laboratory results. For certain patient groups, regular monitoring of blood tests, including markers for kidney function, liver enzymes, and hematology, is required by regulatory bodies.


Q: Is Quando a controlled substance?

No, Quando (Lornoxicam) is officially categorized as a Nonsteroidal Anti-Inflammatory Drug (NSAID). It is generally not classified or listed as a controlled substance by major government drug agencies.


Q: Is Quando secreted into breast milk?

Official regulatory guidance advises that Lornoxicam should be avoided by nursing mothers while breastfeeding. This prohibition is based on the potential risk to the infant.


Q: Is there an official patient leaflet or information sheet for Quando?

Yes, regulatory bodies, such as those in Europe, provide publicly available documents like the Patient Information Leaflet (PIL). This sheet summarizes the drug's use, safety, and administration for patients.


Q: Is it normal to feel a slight headache when first taking Quando?

Yes, regulatory documents list headache as one of the common side effects of Lornoxicam. It is typically considered a mild adverse reaction.


Q: What happens if I accidentally take more Quando than prescribed?

Official overdose information states that taking too much Quando may lead to increased side effects. These may affect the nervous system (e.g., dizziness or convulsions), or cause potential issues affecting liver, kidney, or blood clotting function.


Q: Does Quando treat the underlying cause of the condition or just the symptoms?

Official documents describe Quando as having a dual action. It provides pain relief (symptom management) and also has an anti-inflammatory effect by reducing prostaglandins, which addresses a key physiological mechanism of inflammation.


Q: Can I cut or crush Quando tablets?

Regulatory documents describe the specific method of administration for the tablets. They do not contain instructions to cut or crush the tablets, and altering the form may affect how the body absorbs the medicine.

How should Quando be stored and disposed of?

How to Store and Dispose of Quandō

This information details the official storage, handling, and disposal requirements as mandated by regulatory labeling.


Storage Requirements

Classification Requirement
Temperature Store at Controlled Room Temperature, 20 C to 25 C (68 F to 77 F).
Handling Keep in the original container to protect from moisture and light. Do not freeze.
Child Safety Keep Quandō and all medicines secured out of the sight and reach of children and pets.
Stability If applicable, adhere to the specific in-use stability period (e.g., discard after X days) once the container is opened or the product is reconstituted.

Disposal Instructions

Expired or unused Quandō should be disposed of by following authorized pharmaceutical take-back programs. If a take-back program is unavailable, mix the medicine with an unappealing substance, place it in a sealed bag, and discard it in household trash. Do not dispose of this medication by flushing it down a toilet or pouring it down a sink, unless the regulatory label explicitly states it is safe to do so.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Quando found in:

A-Z Index: